Pi3k inhibitors for treating cough
AssigneeGlaxosmithkline Intellectual Property (No.2) Limited
InventorEmilio Merlo Pich
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of cough, in particular idiopathic chronic cough, cough variant asthma, cough associated with thoracic tumour or lung cancer, viral and post-viral cough, upper airways cough syndrome (UACS) or post nasal drip cough, and cough associated with disorders such as gastro oesophageal reflux disease (both acid and non acid reflux), chronic bronchitis, chronic obstructive pulmonary disease (COPD), interstitial lung disease (such as idiopathic pulmonary fibrosis (IPF)), congestive heart disease, sarcoidosis and infection (such as whooping cough.
Claims7
A method of treating cough comprising administering a safe and effective amount of a compound of formula (I):
- wherein
- X is —CH— and Y is 4-pyridazinyl;
- or
- X is —N— and Y is 4-morpholinyl;
- or a pharmaceutically acceptable salt thereof to a patient in need thereof.
2-5. (canceled)
A method of treating cough comprising administering a safe and effective amount of a compound which is 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, represented by the structure:
- or a pharmaceutically acceptable salt thereof to a patient in need thereof.
A method of treating cough comprising administering a safe and effective amount of a compound which is 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, represented by the structure:
- to a patient in need thereof.
Dependencies are inferred from the claim text.